Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population

Dec 7, 2007Schizophrenia research

Weight gain after one year from haloperidol, risperidone, and olanzapine in people new to these medications: results from a clinical trial

AI simplified

Psychedelic Science on OpenScience ↗PubMed ↗DOI ↗

Abstract

After 1 year of treatment, drug-naïve patients gained an average of 10.9 kg with olanzapine.

Weight gain at 3 months was significantly different among the drugs: 3.8 kg for haloperidol, 5.9 kg for risperidone, and 8.4 kg for olanzapine.
By 12 months, the differences in weight gain among the medications were no longer statistically significant.
Final weight gain after 1 year was 9.7 kg for haloperidol, 8.9 kg for risperidone, and 10.9 kg for olanzapine.
The overall weight gain observed in drug-naïve patients was substantial across all three antipsychotic treatments.

AI simplified

BACKGROUND: There is little information about weight gain induced by antipsychotics at long-term.

OBJECTIVE: To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment.

METHODS: This is a prospective, randomized clinical trial, including a representative sample of first episode psychotic incident cases from a population area of 555.000 people. The main outcome measures were changes in body weight and body mass index at 3 months and at 12 months. Both a per protocol analysis and an intention to treat analysis were conducted.

RESULTS: A total of 164 drug-naïve patients were included. At 12 months 144 patients were evaluated. Of them, 66% completed the protocol and 34% needed treatment switch. We found statistically significant differences in weight gain at 3 months: 3.8 kg (+/-4.1) for haloperidol, 5.9 kg (+/-5.1) for risperidone and 8.4 kg (+/-5.0) for olanzapine (F=7.045; p=0.002). After 1 year the difference in weight gain had disappeared: 9.7 kg (+/-5.7) for haloperidol, 8.9 kg (+/-8.8) for risperidone and 10.9 kg (+/-7.2) for olanzapine (F=0.817; p=0.445).

CONCLUSIONS: Drug-naïve patients experience an extraordinary weight gain after 1 year of treatment with haloperidol, olanzapine or risperidone. The main difference among these treatments is the pattern of weight gain but not the final amount of weight gain.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief